<p>A randomized, double-blind, parallel-group, placebo-controlled, event-driven trial conducted to evaluate the effects of SGLT2 inhibition with empagliflozin on major heart failure outcomes in patients with heart failure and a preserved ejection fraction.</p>

A randomized, double-blind, parallel-group, placebo-controlled, event-driven trial conducted to evaluate the effects of SGLT2 inhibition with empagliflozin on major heart failure outcomes in patients with heart failure and a preserved ejection fraction.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.

Share Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Sign up to save your podcasts

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Empagliflozin in Heart Failure with a Preserved Ejection Fraction